Abstract
Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). Impairments of the NO-sGC signaling pathway have been implicated in the pathogenesis of cardiovascular and other diseases. Direct stimulation of sGC represents a promising therapeutic strategy particularly for the treatment of pulmonary hypertension (PH), a disabling disease associated with a poor prognosis. Previous sGC stimulators such as the pyrazolopyridines BAY 41-2272 and BAY41-8543 demonstrated beneficial effects in experimental models of PH, but were associated with unfavorable drug metabolism and pharmacokinetic (DMPK) properties. Herein we disclose an extended SAR exploration of this compound class to address these issues. Our efforts led to the identification of the potent sGC stimulator riociguat, which exhibits an improved DMPK profile and exerts strong effects on pulmonary hemodynamics and exercise capacity in patients with PH. Riociguat (BAY 63-2521) is currently being investigated in phase III clinical trials for the oral treatment of PH.
Highlights
Joachim Mittendorf1, Stefan Weigand1,4, Cristina Alonso-Alija1, Erwin Bischoff2, Achim Feurer1,5, Michael Gerisch3, Armin Kern3, Andreas Knorr2, Dieter Lang3, Klaus Muenter2, Martin Radtke3, Hartmut Schirok1, Karl-Heinz Schlemmer3, Elke Stahl3, Alexander Straub1, Frank Wunder2 and Johannes-Peter Stasch*2
4th International Conference of cGMP Generators, Effectors and Therapeutic Implications Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2210-9-S1-info.pdf
Soluble guanylate cyclase is a key signal-transduction enzyme activated by nitric oxide (NO)
Summary
Joachim Mittendorf1, Stefan Weigand1,4, Cristina Alonso-Alija1, Erwin Bischoff2, Achim Feurer1,5, Michael Gerisch3, Armin Kern3, Andreas Knorr2, Dieter Lang3, Klaus Muenter2, Martin Radtke3, Hartmut Schirok1, Karl-Heinz Schlemmer3, Elke Stahl3, Alexander Straub1, Frank Wunder2 and Johannes-Peter Stasch*2. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension Address: 1Bayer Schering Pharma AG, Medicinal Chemistry Wuppertal, Pharma Research Center, 42096 Wuppertal, Germany, 2Bayer Schering Pharma AG, Cardiovascular Research, Pharma Research Center, 42096 Wuppertal, Germany, 3Bayer Schering Pharma AG, DMPK, Pharma Research Center, 42096 Wuppertal, Germany, 4Roche, Nonnenwald 2, 82377
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
